title: Direct hemoperfusion with polymyxin B immobilized fiber for abdominal sepsis in Europe.
abstract: Since direct hemoperfusion with polymyxin B immobilized fiber (PMX-DHP) received its product certification for use in Europe in 1998, several prospective randomized controlled trials (RCTs) have been conducted in European countries. The first RCT, performed in six European academic medical centers in 2005, concluded that PMX-DHP is associated with improved hemodynamic status and cardiac function. Subsequently, a meta-analysis of PMX-DHP was presented in Italy in 2007. This systematic review found positive effects of PMX-DHP on mean arterial pressure and dopamine/ dobutamine use, PaO2/FiO2 ratio, endotoxin removal, and mortality. However, like most trials on extracorporeal therapies, none of the studies was double-blinded. The EUPHAS study, a multicenter RCT performed in ten Italian intensive care units in 2009, found that PMX-DHP improved 28-day survival, blood pressure, vasopressor requirement, and degree of organ failure. However, investigators in Belgium and Canada pointed out that there was no statistical difference in 28-day survival. Two more RCTs, the ABDO-MIX and EUPHRATES studies, the primary end points of which are 28-day mortality, were started in Europe and the United States at the end of 2010. We are hoping that these RCTs will resolve this issue.
authors.affiliation: Department of Surgery, Juntendo Shizuoka Hospital, Juntendo University School of Medicine, 1129 Izunokuni, Shizuoka, 410-2295, Japan.
authors.forename: Koichi
authors.initials: K
authors.lastname: Sato
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Maekawa
authors.forename: Mutsumi
authors.initials: M
authors.lastname: Sakurada
authors.forename: Hajime
authors.initials: H
authors.lastname: Orita
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Komatsu
mesh_terms: D000005:Abdomen; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D004731:Endotoxins / Q000097:blood; D005060:Europe; D006464:Hemoperfusion; D006801:Humans; D015201:Meta-Analysis as Topic; D011112:Polymyxin B / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic; D018805:Sepsis / Q000097:blood / Q000188:drug therapy*
chemical_list: D000900:Anti-Bacterial Agents; D004731:Endotoxins; D011112:Polymyxin B